PMID- 10969791
OWN - NLM
STAT- MEDLINE
DCOM- 20000914
LR  - 20181130
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 60
IP  - 16
DP  - 2000 Aug 15
TI  - Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for 
      efficient tumor cell lysis.
PG  - 4446-52
AB  - Dendritic cells (DCs) phagocytose apoptotic influenza-infected monocytes and 
      cross-present influenza antigen to CD8+ T cells, generating a specific CTL 
      response. We investigated whether apoptotic melanoma cells, presented by this 
      mechanism, can lead to CTL responses to tumor-associated antigens and melanoma 
      cells. Apoptotic HLA-A2- MEL-397 melanoma cells were internalized by HLA-A2+ 
      immature monocyte-derived DCs but failed to induce maturation of DCs. When 
      exposed to interleukin 6, interleukin 1beta, tumor necrosis factor alpha, and 
      prostaglandin E2, DCs containing apoptotic MEL-397 cell material matured normally 
      [cross-presenting DCs (cp-DCs)]. Autologous CD8+ CTL lines generated with cp-DCs 
      produced tumor necrosis factor when stimulated with HLA-A2-binding immunodominant 
      peptides from MelanA/MART1 and MAGE-3 (expressed by MEL-397 cells) but not 
      tyrosinase (absent in MEL-397). T2 target cells loaded with the respective 
      peptides were lysed by these cell lines, although to a lesser extent than by CTL 
      lines generated in the presence of mature DCs and peptides from 
      melanoma-associated h antigens. In contrast, lines generated with cp-DCs lysed 
      HLA-A2+ MEL-526 melanoma cells or allogenic HLA-A2+ cp-DCs efficiently, whereas 
      the CTL generated with DCs and peptides had little lytic activity. Mature DCs 
      containing apoptotic tumor cells may thus represent an alternative approach for 
      the therapy of malignant tumors.
FAU - Jenne, L
AU  - Jenne L
AD  - Department of Dermatology, University Hospital Geneva, Switzerland.
FAU - Arrighi, J F
AU  - Arrighi JF
FAU - Jonuleit, H
AU  - Jonuleit H
FAU - Saurat, J H
AU  - Saurat JH
FAU - Hauser, C
AU  - Hauser C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Immunodominant Epitopes)
RN  - 0 (MAGEA3 protein, human)
RN  - 0 (MART-1 Antigen)
RN  - 0 (MLANA protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - EC 1.14.18.1 (Monophenol Monooxygenase)
SB  - IM
MH  - Antigen Presentation/*immunology
MH  - *Antigens, Neoplasm
MH  - Apoptosis/*immunology
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Cytotoxicity, Immunologic/immunology
MH  - Dendritic Cells/*immunology
MH  - Epitopes, T-Lymphocyte/immunology
MH  - HLA-A2 Antigen/biosynthesis/immunology
MH  - Humans
MH  - Immunodominant Epitopes/immunology
MH  - Immunotherapy/methods
MH  - Lymphocyte Activation/immunology
MH  - MART-1 Antigen
MH  - Melanoma/*immunology/pathology/therapy
MH  - Monophenol Monooxygenase/immunology
MH  - Neoplasm Proteins/immunology
MH  - Peptide Fragments/immunology
MH  - Phagocytosis
MH  - T-Lymphocytes, Cytotoxic/immunology/metabolism
MH  - Tumor Cells, Cultured
MH  - Tumor Necrosis Factor-alpha/immunology/metabolism
EDAT- 2000/09/02 11:00
MHDA- 2000/09/19 11:01
CRDT- 2000/09/02 11:00
PHST- 2000/09/02 11:00 [pubmed]
PHST- 2000/09/19 11:01 [medline]
PHST- 2000/09/02 11:00 [entrez]
PST - ppublish
SO  - Cancer Res. 2000 Aug 15;60(16):4446-52.